BioSpace News Archive

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces the publication of new results in the peer-reviewed journal Immunology demonstrating that TRE-515 improved multiple sclerosis (MS) symptoms in mouse models.

eMolecules, Inc., provider of a leading chemistry search-and-fulfillment platform for early drug discovery research, announced the acquisitions of Frontier Scientific Inc. and Frontier Agricultural Sciences Inc. Financial terms of the transactions were not disclosed.

Medline has invested an additional $500 million in incremental medical supply inventory to ensure product availability and timely delivery to the healthcare providers it serves.

Amgen will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress at 1:30 p.m. ET on Monday, Sept. 12, 2022.

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 11:00 AM ET at the Lotte New York Palace Hotel in New York, NY.

UroGen Pharma Ltd. announced that it will present at the following healthcare conferences in September.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced enrollment of the first patient in ROADSTER 3, the first prospective, multi-center, single-arm study to assess real-world treatment of standard surgical risk (SSR) patients with carotid artery disease using TCAR.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for a poster presentation at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics.